Correction to: Nature Medicine https://doi.org/10.1038/s41591-023-02668-y, published online 17 November 2023. In the version of the article initially published, the colors in the Fig. 2 key were switched and have now been amended so that teal represents “Prior BRAFi/MEKi” and orange represents “BRAFi/MEKi-naive”. Additionally, in Fig. 2a, the tenth bar from the left was teal and has now been corrected to orange as the patient was BRAFi/MEKi-naive.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Devorah Segal
Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial - Nature Medicine
Correction to: Nature Medicine https://doi.org/10.1038/s41591-023-02668-y, published online 17 November 2023. In the version of the article initially published, in the third paragraph of the “RAPNO criteria (secondary endpoints)” section, the text now reading “Thirteen (17.1%) patients initially had a best overall response of PD…” originally read “Thirty-one patients initially had PD…”. This has been corrected in the HTML and PDF versions of the article.
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial - Nature Medicine
Abstract BRAF genomic alterations are the most common oncogenic drivers in pediatric low-grade glioma (pLGG). Arm 1 (n = 77) of the ongoing phase 2 FIREFLY-1 (PNOC026) trial investigated the efficacy of the oral, selective, central nervous system–penetrant, type II RAF inhibitor tovorafenib (420 mg m−2 once weekly; 600 mg maximum) in patients with BRAF-altered, relapsed/refractory pLGG.
Treatment for Spinal Muscular Atrophy
By Renatta Knox, MD, PhD, and Devorah Segal, MD, PhD Dr. Knox is Pediatric Neurology Resident, Department of Pediatrics, Division of Child Neurology, Weill Cornell Medicine/New York Presbyterian Hospital, New York. Dr. Segal is Assistant Professor of Clinical Pediatrics, Weill Cornell Medical College Dr. Knox and Dr. Segal report no financial relationships relevant to this field of study.
Migraine Prophylaxis in Children
By Devorah Segal, MD, PhD Assistant Professor of Clinical Pediatrics, Division of Child Neurology, Weill Cornell Medical College Dr. Segal reports no financial relationships relevant to this field of study. SYNOPSIS: In a randomized, double-blind, placebo-controlled trial of migraine prophylaxis in children ages 8-17 years, treatment with neither amitriptyline nor topiramate showed significant differences in headache frequency or headache-related disability compared to placebo.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Devorah
Contact Devorah, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack